Beruflich Dokumente
Kultur Dokumente
org)
Overview
BREAST CANCER
Life cycle changes
Risk factors
Pathogenesis (hormone sensitive)
Clinical features
Eric Wong (http://www.pathophys.org/author/wongeric/), Sultan Chaudhry (http://www.pathophys.org/author/sultan/) and Marisa Rossi
Diagnosis
(http://www.pathophys.org/author/mrossi/)
Screening
Treatment
Overview
Definition: breast cancer refers to several types of neoplasm arising from breast tissue, the most common being adenocarcinoma
of the cells lining the terminal duct lobular unit. This chapter only discusses this adenocarcinoma type.
Breast cancer is the most prevalent cancer in Canadian women, and is the second leading cause of cancer deaths in women.
However, the prognosis is good if detected early. The overall 5-year relative survival is 88% in women.
Canadian Cancer Society Statistics 2012
Hormonal cancer: breast cancer requires a hormonal supply to develop, much like the tissue it arises out of. Risk of breast cancer
increases with lifetime estrogen exposure. The majority of breast cancers are hormone sensitive, meaning that they express
estrogen receptors and proliferate in response to estrogen stimulation. Endocrine therapies that inhibit estrogen production are
effective in treating hormone-sensitive breast cancer.
Hereditary cancer: approximately 5-10% of breast cancers are hereditary, meaning that there is a known genetic mutation causing
increased cancer risk in the patient’s family. Hereditary breast and ovarian cancer (HBOC) syndrome is caused by mutations in
two genes, BRCA1 and BRCA2. The genes code for a DNA repair pathway that is important for protecting against mutations. The
loss of either gene confers a high risk of breast cancer, as well as other cancers.
Feedback
(http://www.pathophys.org/breast-cancer/breastnormal-copy/)
Overview
Life cycle changes
Risk factors
Pathogenesis (hormone sensitive)
Clinical features
Diagnosis
Screening
Treatment
(http://www.pathophys.org/breast-cancer/breast-cancer-life-cycle-changes/)
Risk factors
Gender Female: Primary risk factor. Lifetime risk in females is 1:8 compared
to males at 1:1000.
Crit Rev Oncol Hematol.
(http://www.ncbi.nlm.nih.gov/pubmed/19427229#) 2010 Feb;73(2):141-
55.
Age Aging: Risk increases with advancing age. Risk at age 40 is 1:217 and
risk at age 80 is 1:10.
Height and weight Height: Taller women, both pre- and postmenopausal, have a slightly
Feedback
increased risk; likely correlated with hormonal stimulation.
Arch Intern Med.
(http://www.ncbi.nlm.nih.gov/pubmed/17130395#) 2006 Nov
27;166(21):2395-402.
Reproductive history Early age (<12) at menarche and late age (>55) at menopause: Risk
increases linearly with the cumulative number of ovulatory cycles.
Proliferation of breast epithelium occurs in the luteal phase of the
ovulatory cycle, thereby increasing risk of promotion of initiated cells
(see Carcinogenesis (http://www.pathophys.org/introneoplasia/)
chapter).
Late age (>35) of first full-term birth and nulliparity: Pregnancy
induces terminal differentiation of luminal cells by exposing the tissue
to human chorionic gonadotrophin (hCG). Breast gene expression
changes permanently after pregnancy, increasing DNA repair pathways
and control over apoptosis. However, pregnancy itself causes a
CONTENTS
transient risk of breast cancer because of increased estrogen and
Overview progesterone exposure, which promotes proliferation in initiated cells.
Life cycle changes Late age at first full-term birth increases time for exposure to
Risk factors carcinogens.
J Mammary Gland Biol Neoplasia.
Pathogenesis (hormone sensitive)
(http://www.ncbi.nlm.nih.gov/pubmed/21805333#) 2011 Sep;16(3):221-
Clinical features 33.
Nat Rev Cancer.
Diagnosis
(http://www.ncbi.nlm.nih.gov/pubmed/16557280#) 2006 Apr;6(4):281-
Screening 91.
Treatment
Exposure history Hormone replacement therapy (HRT): Combined estrogen and
progesterone therapy has been linked to the development of breast
cancer in postmenopausal women; not estrogen alone. Oral
contraceptives (OCP) do not increase risk. Estrogen and progesterone
in HRT likely promotes preneoplastic lesions rather than initiate them.
Since OCP is used in younger women, the number of preneoplastic
lesions is much lower than in postmenopausal women, rendering the
OCP risk much lower.
JAMA. (http://www.ncbi.nlm.nih.gov/pubmed/12824205#) 2003 Jun
25;289(24):3243-53.
JAMA. (http://www.ncbi.nlm.nih.gov/pubmed/20959578#) 2010 Oct
20;304(15):1684-92.
Nat Rev Clin Oncol.
(http://www.ncbi.nlm.nih.gov/pubmed/21808267#) 2011 Aug
2;8(11):669-76.
Feedback
Ionizing radiation: Breast tissue is sensitive to carcinogenic effects of
radiation. Risk is highest in the developing breast and absent after
menopause. See Carcinogenesis
(http://www.pathophys.org/introneoplasia/#Chapter_4_Carcinogenesis)
chapter for mechanism of ionizing radiation.
Breast Cancer Res.
(http://www.ncbi.nlm.nih.gov/pubmed/15642178#) 2005;7(1):21-32.
Risk factors Cowden syndrome: Characterized by high rate of breast cancer and
Pathogenesis (hormone sensitive) mucocutaneous findings, thyroid disorders and endometrial
Clinical features carcinomas. Associated germline mutations in the PTEN* gene.
(lifetime risk = 50%)
Diagnosis
Screening
BRCA1/2 mutations 5-10% breast cancer cases are considered directly related to inheritance
Treatment of mutations in BRCA1 or BRCA2. Women carrying mutations in
BRCA1/2 genes have a 50-80% lifetime risk of breast cancer.
Nat Rev Clin Oncol.
(http://www.ncbi.nlm.nih.gov/pubmed/20956982#) 2010 Dec;7(12):702-7. BRCA1 gene is located on chromosome 17q21 and is classified as a
J Cell Sci. tumour suppressor gene. It functions as a pleiotropic DNA damage
(http://www.ncbi.nlm.nih.gov/pubmed/11707511#) 2001 Oct;114(Pt 20):3591- repair protein. Its mutation is associated with basal-like phenotype of
8.
breast cancer, high grade III subtype, high mitotic count, and triple
Nat Rev Cancer.
negative (ER/PR/HER2) carcinomas
(http://www.ncbi.nlm.nih.gov/pubmed/22193408#) 2011 Dec 23;12(1):68-78.
Feedback
(II or III) when compared to age-matched sporadic cases
Both ER subtypes carry a DNA binding domain and exist in the nucleus and the cytosol. When estrogen enters the cell, it binds the ER and the
complex migrates into the nucleus and leads to the production of transcription proteins that induces changes in the cell. Therefore, due to estrogen’s
proliferative properties, its cellular stimulation can have negative consequences in patients expressing large quantities of these receptors
intracellularly.
CONTENTS
Overview
Life cycle changes
Risk factors
Pathogenesis (hormone sensitive)
Clinical features
Diagnosis
Screening
Treatment
Feedback
(http://www.pathophys.org/breast-cancer/breastcancer-copy/)
Clinical features
Med Clin North Am. (http://www.ncbi.nlm.nih.gov/pubmed/18721655#) 2008 Sep;92(5):1115-41, x.
Mayo Clin Proc. (http://www.ncbi.nlm.nih.gov/pubmed/11393504#) 2001 Jun;76(6):641-7; quiz 647-8.
Very few clinical signs and symptoms exist for breast cancer raising the importance of screening tests in diagnosis.
Benign Malignant
Breast mass – a dominant mass is a distinct mass that is Absence of discrete lump Discrete lump
asymmetric with the other breast. Benign findings are often Mobile Fixed
associated with cysts, fibroadenomas, or fibrocystic changes. Soft Firm
Malignant disease often has abnormal cell proliferation and Smooth borders Irregular borders
calcifications, manifesting as a fixed, firm mass with irregular Tender Non-tender
borders. Any suspicious dominant mass should undergo diagnostic
tests (see below).
Nipple discharge – usually benign, but discharge with blood, from Milky, green or yellow Bloody or serous
a single duct, or associated with breast mass raises probability of Multiple duct Single duct
cancer. Produced with manual Produced spontaneously
expression
Mastalgia (breast pain) – rarely the presenting symptom of breast Bilateral Focal
cancer Diffuse
Worse during the late luteal
Cyclic mastalgia: Hormonal changes during the menstrual cycle phase of menstrual cycle
trigger an increase in breast size and volume. Subsides with onset of
CONTENTS
menstruation
Overview
SOB/dyspnea Metastatic disease to the lungs
Life cycle changes
Bone
Riskpain and symptoms of hypercalcemia
factors Bone metastasis
Pathogenesis (hormone sensitive)
Abdominal distention and jaundice Liver and peritoneal metastasis
Clinical features
Altered cognitive function and local neurological signs
Diagnosis Brain metastasis
Screening
Diagnosis
Treatment
Multistep approach:
Mammogram has a false negative rate of 11%. It is accurate in detecting calcifications as well as small non-palpable lesion in
postmenopausal women with non-dense breast tissue.
Ultrasound is better at detecting fluid-filled lesions (cysts) and small tumours in dense breast tissue.
3) Biopsy or fine needle aspiration is done if a lump is detected by imaging or if clinically it appears suspicious.
Staging is done using the TNM system (see Introduction to neoplasia (http://www.pathophys.org/introneoplasia/)chapter), but
Feedback
molecular markers (see above) correlate better with prognosis.
Screening
CMAJ. (http://www.ncbi.nlm.nih.gov/pubmed/22106103#) 2011 Nov 22;183(17):1991-2001.
Evidence
Screening with mammography every 2-3 years for women of average risk (i.e. no family history, no BRCA mutations) from age 40-
74 is associated with reduced mortality.
Women at increased risk of breast cancer should undergo regular screening by imaging and breast examination at a younger
age.
Screening with clinical breast examination or breast self-examination is not associated with reduction in mortality.
Current Canadian guidelines recommend the following for women of average risk
No routine screening for women aged 40-49 due to high number of false positives on mammogram and unnecessary biopsies
compared to mortality benefit.
Routine mammography every 2-3 years for women aged 50-74 due to mortality benefit outweighing false positive and unnecessary
biopsy risk.
Routine breast self-examination and clinical breast examinations are not recommended.
Discussion of this data with patients allows more autonomy for a personalized screening schedule.
Treatment
Lancet. (http://www.ncbi.nlm.nih.gov/pubmed/15894099#) 2005 May 14-20;365(9472):1727-41.
Surgery
CMAJ. (http://www.ncbi.nlm.nih.gov/pubmed/9484274#) 1998 Feb 10;158 Suppl 3:S15-21.
Breast-conserving surgery (BSC): also known as lumpectomy or wide local excision, BSC involves resection of the tumour along
with a margin of tissue while conserving the cosmetic appearance of the breast. Most breast surgeries are of this type because (i)
most tumours are locally invasive and (ii) large primary tumours can be reduced in size by neoadjuvant chemotherapy prior to
conservative surgery.
Mastectomy: surgical removal of entire breast, including the fascia over the pectoralis muscles. Surgeons may preserve some skin
and the nipple/areola for reconstruction. The indication for mastectomy is multicentric invasive carcinoma, inflammatory carcinoma,
or extensive intraductal carcinomas.
Axillary lymph node dissection: removal of the lymph nodes draining the breast tissue for lymph node micrometastasis. This is
CONTENTS
done at the same time as BSC or mastectomy. However, recent evidence suggests that axillary lymph node biopsy is unnecessary
Overview
regardless of whether the sentinel lymph node biopsy is negative or positive because there is no mortality benefit.
Life cycle changes
Ann Surg Oncol. (http://www.ncbi.nlm.nih.gov/pubmed/20853057#) 2010 Oct;17 Suppl 3:343-51.
Risk factorstherapy: cytotoxic chemotherapy, endocrine therapy, or radiation therapy may be used postsurgery to prevent relapse.
Adjuvant
Pathogenesis (hormone sensitive)
Radiation therapy
Clinical features
Either whole or partial breast irradiation may be used (see Carcinogenesis (http://www.pathophys.org/introneoplasia/) chapter for
Diagnosis
mechanism of radiation therapy). Adjuvant radiation therapy is applied post-BCS or post-mastectomy to prevent recurrence. Since
Screening
most recurrence of early-stage breast cancer occurs locally, partial irradiation at the tumour site has similar mortality benefits as
Treatment
whole breast irradiation. However, new evidence suggests an increased risk of local and axillary recurrence with partial irradiation.
Breast J. (http://www.ncbi.nlm.nih.gov/pubmed/20210799#) 2010 May-Jun;16(3):245-51.
Radiation of metastatic disease (e.g. bone or brain metastases) is also used.
Endocrine therapy
Best Pract Res Clin Endocrinol Metab. (http://www.ncbi.nlm.nih.gov/pubmed/14687595#) 2004 Mar;18(1):1-32.
Breast cancer is a hormone-sensitive cancer. Most breast cancer cells are ER-positive, and thus will respond to reduction of
circulating estrogens. HR-negative breast cancers will not respond to endocrine therapy.
Mainly used as (i) adjuvant therapy for early-stage hormone-sensitive breast cancer or as (ii) first line therapy for metastatic
hormone-sensitive breast cancer.
Cancer Care Ontario recommends 5 years of adjuvant endocrine therapy for early-stage breast cancer in postmenopausal
women.
Antiestrogens (e.g. tamoxifen): Competitively binds ER and inhibits estrogen binding.
Aromatase inhibitors: Aromatase, also known as estrogen synthase, is an enzyme responsible for estrogen synthesis. There are
two types: steroidal (type I) and non-steroidal (type II). The steroidal type (e.g. exemestane) is an androgen analogue that binds
Feedback
permanently with the aromatase enzyme, leading to long-term and specific inhibition of the enzyme. The non-steroidal type (e.g.
anastrozole and letrozole) originates from an anti-epileptic drug that reversibly binds and inhibits the cytochrome P450 unit in
aromatase. Because the non-steroidal type has a good molecular fit with the substrate-binding site, it is more potent than the
steroidal type. Both types have good efficacy and high specificity for the aromatase enzyme.
Ovarian ablation: induction of artificial menopause by ovariectomy significantly reduces breast cancer risk. Adrenalectomy
eliminates a source of androgens in females, which is the precursor to aromatase-derived estrogens. However, these surgical
approaches are irreversible and cause major side effects, so they are less often used.
Ovarian suppression: LHRH (GnRH) agonist (e.g. goserelin and leuprorelin) can be used to reversibly suppress LH/FSH
release and thus estrogen release.
Chemotherapy
Cytotoxic drugs, such as cyclophosphamide, methotrexate, doxorubicin, and paclitaxel, are used in hormone receptor-negative or
HER2-positive breast cancers. They can either be given presurgery as neoadjuvant to shrink the tumour or postsurgery as
adjuvant to prevent relapse.
McMaster
Pathophysiology
Review
Concise, up-to-date, faculty-reviewed articles on the pathophysiology of disease.
Please see instructions for terms of use. (http://www.pathophys.org/instructions/)
UNITS
Cardiology (http://www.pathophys.org/category/cardiology/)
Endocrinology (http://www.pathophys.org/category/endocrinology/)
Gastroenterology (http://www.pathophys.org/category/gi/)
Genetics (http://www.pathophys.org/category/genetics/)
Hematology (http://www.pathophys.org/category/hematology/)
Infectious diseases (http://www.pathophys.org/category/id/)
Nephrology (http://www.pathophys.org/category/nephrology/)
Neurology (http://www.pathophys.org/category/neurology/)
Obstetrics and gynecology (http://www.pathophys.org/category/obgyn/)
Oncology
CONTENTS (http://www.pathophys.org/category/oncology/)
Pediatrics (http://www.pathophys.org/category/pediatrics/)
Overview
Respirology (http://www.pathophys.org/category/respirology/)
Life cycle changes
Rheumatology (http://www.pathophys.org/category/rheum/)
Risk factors
USEFULPathogenesis
LINKS (hormone sensitive)
McMaster Health Sciences Library (http://hsl.mcmaster.ca/)
Clinical features
McMaster University (http://www.mcmaster.ca)
Diagnosis
Medportal (http://www.medportal.ca)
Screening
Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/)
Treatment
Copyright © 2012-2018 McMaster Pathophysiology Review (MPR). All rights reserved. 320press (http://320press.com)
Feedback